A5019667932- Cancer Genomics and Diagnostics
- Genetics, Bioinformatics, and Biomedical Research
- Parkinson's Disease Mechanisms and Treatments
- Immunotherapy and Immune Responses
- Cell Image Analysis Techniques
- Diet and metabolism studies
- RNA regulation and disease
- Genetic factors in colorectal cancer
- Reproductive System and Pregnancy
- Liver Disease Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Economic and Financial Impacts of Cancer
- T-cell and B-cell Immunology
- Gut microbiota and health
- Dementia and Cognitive Impairment Research
- Advances in Oncology and Radiotherapy
- Lung Cancer Treatments and Mutations
- Health, Environment, Cognitive Aging
- Diabetes Treatment and Management
- RNA Interference and Gene Delivery
- Neurological diseases and metabolism
- COVID-19 and healthcare impacts
- Health and Medical Research Impacts
- Health Systems, Economic Evaluations, Quality of Life
- Alzheimer's disease research and treatments
Laboratoire National de Santé
2024
Luxembourg Institute of Health
2022
Institut National du Cancer
2021
National Library of Luxembourg
2015-2016
Central Bank of Luxembourg
2014-2015
RWTH Aachen University
2005
Max Delbrück Center
2005
Parkinson's disease (PD) is a systemic clinically defined by the degeneration of dopaminergic neurons in brain. While alterations gut microbiome composition have been reported PD, their functional consequences remain unclear. Herein, we addressed this question an analysis stool samples from Luxembourg Study (n = 147 typical PD cases, n 162 controls).All individuals underwent detailed clinical assessment, including neurological examinations and neuropsychological tests followed self-reporting...
Biobanks are important resources for biomarker discovery and assay development. Biomarkers Alzheimer's Parkinson's Disease (BIOMARKAPD) is a European multicenter study, funded by the EU Joint Programme - Neurodegenerative Research (JPND), that aims to improve clinical use of body fluid markers diagnosis prognosis disease (AD) (PD). The objective was standardize assessment existing assays validate novel biomarkers AD PD. To support validation assays, central virtual biobank fluids associated...
Several phenotypic differences observed in Parkinson's disease (PD) patients have been linked to age at onset (AAO). We endeavoured find out whether these are due the ageing process itself by using a combined dataset of idiopathic PD (n = 430) and healthy controls (HC; n 556) excluding carriers known PD-linked genetic mutations both groups. found several significant effects AAO on motor non-motor symptoms PD, but when comparing with HC (using assessment, AAA), only positive associations AAA...
Abstract Bile acids (BAs) are increasingly recognised as metabolic regulators, potentially improving insulin sensitivity following bariatric surgery. However, physiological relevance of such observations remains unknown. Hence, we analysed serum BA composition and associated gut-derived hormone levels lifestyle-induced weight loss in individuals with syndrome (MetS). 74 non-smoking men (45–55 yr) MetS were randomised to a program (supervision via telemonitoring) or control arm. Before after...
Abstract Dendritic cells (DC) represent key regulators of the immune system, yet their development from hemopoietic precursors is poorly defined. In this study, we describe an in vitro system for amplification a Flt3+CD11b+ progenitor mouse bone marrow with specific cytokines. Such develop into both CD11b+ and CD11b− DC, CD8α+ CD8α− DC vivo. Furthermore, GM-CSF, these progenitors synchronously differentiated fully functional vitro. This two-step culture yields homogeneous populations high...
High‐throughput genomic analyses are being implemented in clinical practice. MODIFY is a retrospective study of the first introduction profiling and molecular tumor boards country Luxembourg. The primary objective was to assess whether patients derived benefit by measuring percentage who presented progression‐free survival (PFS) on matched therapy (PFS2) 1.3‐fold longer than PFS previous (PFS1). A total 94 were included. In total, 45 (53.57% with successful next‐generation sequencing [NGS]...
Early detection of neurodegenerative diseases as Alzheimer's and Parkinson's disease (AD PD) is crucial for slowing down the process. Biomarkers are promising such early detection, but not without problems. The use biomarkers challenged by high interlaboratory variability lack plasma markers. JPND project “Biomarkers Disease (BIOMARKAPD)” a European multicentre study that aims to improve clinical body fluid markers diagnosis prognosis AD PD. objectives standardise existing assays validate...
Abstract Mounting evidence indicates that growth of pathologically identical cancers in each individual patient is fueled by different sets driving mutations. The need to identify these drivers stems from the recognized necessity for tailoring therapy and scheduling future surveillance. This personalized medical approach has been shown result better treatment outcomes. We present a novel Precision Cancer Analysis system (PCAS) capable identifying activated signaling pathways means...
Abstract Mounting evidence indicates that growth of pathologically identical cancers in each individual patient is fueled by different sets driving mutations. The need to identify these drivers stems from the recognized necessity for tailoring therapy and scheduling future surveillance. This personalized medical approach has been shown result better treatment outcomes. We present a novel Precision Cancer Analysis system (PCAS) capable identifying activated signaling pathways means...
e22123 Background: As no two tumors share the same molecular mechanism, each cancer patient presents a unique type of disease. Genomic profiling, especially NGS, has armed oncologists with new information leading to major improvements in care. The establishment such tools raised bar for next generation diagnostics overcome challenges 1) Identification clinical significance mutations and interplay within them, most which are classified as variants unknown (VOUS) 2) assessing usefulness...
e23153 Background: Mounting evidence indicates that growth of pathologically identical cancers in each individual patient is fueled by different sets driving mutations. The need to identify these drivers stems from the recognized necessity for tailoring therapy and scheduling future surveillance. This personalized medical approach has been shown result better treatment outcomes. We present a novel Precision Cancer Analysis system (PCAS) capable identifying activated signaling pathways...